{"id":"W3132138449","doi":"10.33380/2305-2066-2021-10-1-31-36","title":"PD-L1 as a Potential Target in Cancer Therapy (Review)","year":2021,"lang":"en","type":"article","venue":"Drug development & registration","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Public Health Association","funders":"","keywords":"Durvalumab; Avelumab; Immunotherapy; Immune system; Cancer; Medicine; Clinical trial; Cancer immunotherapy; Mechanism (biology); Immunology; Cancer research; Internal medicine; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002972641,0.0001412734,0.0002260222,0.00005629263,0.00005685223,0.00001942209,0.0000562629,0.0000556134,0.001436554],"category_scores_gemma":[0.0000212603,0.0001259038,0.00007363578,0.000304935,0.00002912256,0.00008511135,0.00001105759,0.0001154543,0.00002924506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002332729,"about_ca_system_score_gemma":0.001372849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002196004,"about_ca_topic_score_gemma":0.0003689661,"domain_scores_codex":[0.9987768,0.00004938645,0.0003904943,0.0002738818,0.0003215295,0.0001878868],"domain_scores_gemma":[0.999536,0.000007559851,0.000107662,0.0001849467,0.0001117558,0.00005209233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003289,0.001216778,0.01755203,0.001346309,0.0004629778,0.0007906462,0.003464032,0.00002430593,0.1728219,0.0001759088,0.1262752,0.672581],"study_design_scores_gemma":[0.003581141,0.00005538833,0.1344113,0.001692444,0.0000255581,0.0001042434,0.0002421336,0.00003126468,0.09127207,0.00006492469,0.7682049,0.0003146373],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7816477,0.1820895,0.0002599514,0.02432494,0.000728876,0.001097293,0.000006160654,0.00008417106,0.009761469],"genre_scores_gemma":[0.7355728,0.2077188,0.005367555,0.01609749,0.0003341734,0.0004592478,0.0008263163,0.00005083395,0.03357284],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6722664,"threshold_uncertainty_score":0.9994763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01983293940426857,"score_gpt":0.3036877309930628,"score_spread":0.2838547915887942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}